🟢 Eupraxia Pharmaceuticals is trading 7% up in pre-market — no confirmed catalyst identified

Eupraxia Pharmaceuticals is trading at $7.99, up 7.07%, in pre-market; no confirmed catalyst for the move has been identified.

• The company is scheduled to present RESOLVE trial findings at the ACG conference on October 12. The presentation was announced October 9, but no source confirms it drove the move.
• Healthcare is up 1.58% pre-market, but reported strength centers on managed-care stocks, not Eupraxia’s clinical-biotechnology business.